Cardiovascular

Cardiovascular diseases are the most common cause of death among people in the developed world. An important
focus to improve treatment of heart disease is included in the Karolinska Development portfolio and involves targeted
measures against the kinds of inflammation that are often the basis for heart attacks and strokes, both acute and recurrent.

Cardiovascular

Concept Development

Lead Discovery

Lead Optimization

Preclinical Development

Phase I

Phase II

Phase III

Launch

Athera Biotechnologies AB (Annexin A5)

Athera Biotechnologies AB (PC-mAb)

Athera Biotechnologies AB

Athera develops products for the risk assessment and treatment of cardiovascular disease related to inflammatory and immunological mechanisms.

www.athera.se

¹⁾Source: WHO, The Global Burden of Disease: 2004 Update, 2008